News

Portfolio – Nov 22, 2021

Inositec acquired by Vifor Pharma for its program in first-in-class treatment for progressive vascular calcification

Portfolio – Nov 12, 2021

Oculis announces patient dosing in its diamond study DIAMOND, its first phase 3 study with OCS-01

Portfolio – Nov 11, 2021

Araris Biotech AG Expands Scientific Advisory Board with Appointment of Dr. Jeff Sharman and Dr. Clive Stanway

Firm – Nov 05, 2021

Susan M. Gasser, advisor to VI Partners, receives honorary doctorate by University of Fribourg

Portfolio – Oct 25, 2021

Altoida and Ionian University Investigate Breakthrough Software Device for Parkinson’s Disease Diagnosis

Portfolio – Oct 18, 2021

Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University

Portfolio – Oct 13, 2021

Acodis accelerates its growth with a CHF 2.5m financing led by VI Partners

Portfolio – Oct 07, 2021

Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint

Portfolio – Sep 07, 2021

VI Partners increases their investment in existing portfolio company Ledgy, welcoming new lead investor Sequoia Capital in the US$10m Series A round

Portfolio – Aug 16, 2021

JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial

Portfolio – Aug 05, 2021

Altoida Awarded FDA Breakthrough Designation for Development of World’s First Precision Neurology Device for Prediction of Alzheimer’s Disease

Portfolio – Jul 08, 2021

Altoida Secures Funding and Research Partnership with Eisai Innovation to Accelerate Work Towards Predictive Dementia Diagnostics

Portfolio – Jul 08, 2021

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Portfolio – Jul 01, 2021

Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump study – POSEIDON

Portfolio – May 20, 2021

JenaValve Technology Receives CE Mark for its TrilogyTM TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis

Portfolio – May 18, 2021

MerLion Pharmaceuticals Completes Growth Financing Round

Portfolio – May 06, 2021

Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform

Portfolio – May 05, 2021

VI Partners invests in late-stage biopharmaceutical company Oculis

Firm – Apr 14, 2021

Prof. Susan M. Gasser joins VI Partners as advisor

Portfolio – Apr 13, 2021

CeQur Raises $115 Million Series C5 Financing

Portfolio – Apr 02, 2021

Araris appoints Chief Development Officer

Firm – Feb 12, 2021

VI Partners welcomes renowned fintech entrepreneur John Lunn as advisor

Portfolio – Feb 10, 2021

MedLumics closes upsized EUR 18M financing round and appoints new Chairman

Firm – Jan 29, 2021

VI Partners welcomes Asher Siddiqui as Advisor

Insights & Thoughts – Jan 19, 2021

Inositec acquired by Vifor Pharma for its program in first-in-class treatment for progressive vascular calcification

Oculis announces patient dosing in its diamond study DIAMOND, its first phase 3 study with OCS-01

Araris Biotech AG Expands Scientific Advisory Board with Appointment of Dr. Jeff Sharman and Dr. Clive Stanway

Susan M. Gasser, advisor to VI Partners, receives honorary doctorate by University of Fribourg

Altoida and Ionian University Investigate Breakthrough Software Device for Parkinson’s Disease Diagnosis

Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University

Acodis accelerates its growth with a CHF 2.5m financing led by VI Partners

Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint

VI Partners increases their investment in existing portfolio company Ledgy, welcoming new lead investor Sequoia Capital in the US$10m Series A round

JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial

Altoida Awarded FDA Breakthrough Designation for Development of World’s First Precision Neurology Device for Prediction of Alzheimer’s Disease

Altoida Secures Funding and Research Partnership with Eisai Innovation to Accelerate Work Towards Predictive Dementia Diagnostics

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump study – POSEIDON

JenaValve Technology Receives CE Mark for its TrilogyTM TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis

MerLion Pharmaceuticals Completes Growth Financing Round

Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform

VI Partners invests in late-stage biopharmaceutical company Oculis

Prof. Susan M. Gasser joins VI Partners as advisor

CeQur Raises $115 Million Series C5 Financing

Araris appoints Chief Development Officer

VI Partners welcomes renowned fintech entrepreneur John Lunn as advisor

MedLumics closes upsized EUR 18M financing round and appoints new Chairman

VI Partners welcomes Asher Siddiqui as Advisor

“Long on Innovation”: A conversation with Joël Mesot, President, ETH Zurich

Don’t miss out on our  latest company news!

News

Inositec acquired by Vifor Pharma for its program in first-in-class treatment for progressive vascular calcification

Oculis announces patient dosing in its diamond study DIAMOND, its first phase 3 study with OCS-01

Araris Biotech AG Expands Scientific Advisory Board with Appointment of Dr. Jeff Sharman and Dr. Clive Stanway

Susan M. Gasser, advisor to VI Partners, receives honorary doctorate by University of Fribourg

Altoida and Ionian University Investigate Breakthrough Software Device for Parkinson’s Disease Diagnosis

Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University

Acodis accelerates its growth with a CHF 2.5m financing led by VI Partners

Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint

VI Partners increases their investment in existing portfolio company Ledgy, welcoming new lead investor Sequoia Capital in the US$10m Series A round

JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial

Altoida Awarded FDA Breakthrough Designation for Development of World’s First Precision Neurology Device for Prediction of Alzheimer’s Disease

Altoida Secures Funding and Research Partnership with Eisai Innovation to Accelerate Work Towards Predictive Dementia Diagnostics

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump study – POSEIDON

JenaValve Technology Receives CE Mark for its TrilogyTM TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis

MerLion Pharmaceuticals Completes Growth Financing Round

Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform

VI Partners invests in late-stage biopharmaceutical company Oculis

Prof. Susan M. Gasser joins VI Partners as advisor

CeQur Raises $115 Million Series C5 Financing

Araris appoints Chief Development Officer

VI Partners welcomes renowned fintech entrepreneur John Lunn as advisor

MedLumics closes upsized EUR 18M financing round and appoints new Chairman

VI Partners welcomes Asher Siddiqui as Advisor

“Long on Innovation”: A conversation with Joël Mesot, President, ETH Zurich

Don’t miss out on our latest company news!

Don’t miss out on our  latest company news!